We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    betalutin

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

This study is not yet open for participant recruitment.
Verified September 2017 by Nordic Nanovector
Sponsor:
ClinicalTrials.gov Identifier:
NCT02657447
First Posted: January 15, 2016
Last Update Posted: September 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Nordic Nanovector
  Purpose
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed non-Hodgkin lymphoma. The study will also investigate the safety, toxicity and efficacy of Betalutin and pre-dosing.

Condition Intervention Phase
Non-Hodgkin Lymphoma Drug: Betalutin with lilotomab dose 1 Drug: Betalutin with lilotomab dose 2 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma

Resource links provided by NLM:


Further study details as provided by Nordic Nanovector:

Primary Outcome Measures:
  • Dosimetry [ Time Frame: 3 weeks ]
    Estimation of individual tumour/organ uptake and retention of radioactivity.


Secondary Outcome Measures:
  • The number of participants with adverse events as assessed by NCTCAE. [ Time Frame: 12 weeks ]
    Adverse events by treatment group.

  • Efficacy (Best overall response rate) [ Time Frame: 3 months - 1 year ]
    Best overall response rate by treatment group as measured by Cheson Criteria.

  • Lilotomab pharmacokinetics [ Time Frame: 3 weeks ]
    Estimation using decay correction measurements


Estimated Enrollment: 8
Anticipated Study Start Date: October 2017
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: Betalutin with lilotomab dose 1
Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing
Drug: Betalutin with lilotomab dose 1
15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
Other Names:
  • Betalutin
  • Lymrit 37-02
  • lutetium (177Lu) lilotomab satetraxetan
  • HH1
  • 177Lu-DOTA-HH1
Experimental: Arm 2: Betalutin with lilotomab dose 2
Betalutin 15MBq/kg b.w. with lilotomab pre-dosing
Drug: Betalutin with lilotomab dose 2
15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
Other Names:
  • Betalutin
  • Lymrit 37-02
  • lutetium (177Lu) lilotomab satetraxetan
  • HH1
  • 177Lu-DOTA-HH1

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed (by WHO classification) relapsed indolent non-Hodgkin B-cell lymphoma of following subtypes: Follicular lymphoma (follicular grade I-IIIA), Marginal zone lymphoma (exclusion of MZL if large lymphocytes > 50%), Small lymphocytic lymphoma, Lymphoplasmacytoid and classical mantle cell lymphoma (no blastoid MCL).
  2. Requiring initiation of treatment for the NHL.
  3. Relapsed after at least one line of therapy including rituximab combination chemotherapy regimen.
  4. Exhausted and/or ineligible for all standard treatment options.
  5. Not a candidate for an autologous or allogeneic stem cell transplantation. Patients in progression after successful stem cell collection before before high-dose therapy and autologous stem cell transplantation may be considered for enrolment.
  6. Age ≥ 18 years..
  7. A pre-study ECOG performance status of 0-2. In selected patients an ECOG score of 3 can be acceptable if it is clearly lymphoma-associated at the discretion of the investigator.
  8. Life expectancy should be ≥ 3 months.
  9. 9. < 25% tumour cells in bone marrow biopsy prior to lilotomab/Betalutin treatment (biopsy taken from a site not previously irradiated).
  10. All patients must have at least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by CT scan). Patients without such a target lesion can be accepted on an individual basis if histological organ involvement can be evaluated for response e.g. involvement of the skin or the gastrointestinal tract.
  11. Women of childbearing potential must:

    • have a negative serum pregnancy test at screening and before Betalutin injection
    • understand that the study medication is expected to have teratogenic risk
    • agree to use, and be able to comply with, highly effective method of birth control with a Pearl-Index ≤ 1%. Contraception is required without interruption, 4 weeks before starting study drug, throughout study drug therapy and for 12 months after end of study drug therapy, even if she has amenorrhoea.
  12. Male subjects must agree to use condoms during intercourse throughout study drug therapy and the following 12 months.
  13. Patients previously treated with native rituximab are eligible.
  14. The patient is willing and able to comply with the protocol, and agrees to return to the hospital for follow-up visits and examination.
  15. The patient has been fully informed about the study and has signed the informed consent form.
  16. Negative HAMA test.
  17. CD37 positive, re-biopsy or test on existing tumour material if not known

Exclusion Criteria:

  1. Medical contraindications, including uncontrolled infection, severe cardiac, pulmonary, neurologic, psychiatric or metabolic disease, steroid requiring asthma/allergy, known HIV positive.
  2. Laboratory values during screening :

    • Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l
    • Platelet count ≤ 150 x 109 /l
    • Total bilirubin ≥ 30 mmol/l
    • ALP and ALAT ≥ 4x normal level
    • GFR < 60 ml/min/1.73 m2 as measured by the CKD-EPI method.
  3. Known or suspected CNS involvement of lymphoma
  4. Previous total body irradiation, or irradiation of > 25% of the patient's bone marrow.
  5. Chemotherapy, immunotherapy or another investigational drug received within the last 4 weeks prior to the patient entering screening.
  6. Earlier treatment with radioimmunotherapy.
  7. Exposure to another CD37 targeting drug.
  8. Concurrent participation in another therapeutic treatment trial.
  9. Previous hematopoietic stem cell transplantation (autologous and allogenic).
  10. Pregnant or lactating women.
  11. Transformed or potentially transformed NHL from indolent to aggressive
  12. Receipt of live, attenuated vaccine within 30 days prior to enrolment
  13. Test positive for hepatitis B (HBsAg and anti-HBc)
  14. A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any excipient used in rituximab, HH1 or Betalutin
  15. Malignant disease, other than that being treated in this study. Exceptions include: malignancies that were treated curatively and have not recurred within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancers; completely resected carcinoma in situ of any type.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02657447


Contacts
Contact: Laurie Baylor Curtis +44 75950502495 lbaylorcurtis@nordicnanovector.com

Locations
Germany
Universitätsklinikum Würzburg Not yet recruiting
Würzburg, Germany
Sponsors and Collaborators
Nordic Nanovector
Investigators
Principal Investigator: Andreas Buck, Prof. MD Wuerzburg University Hospital
  More Information

Publications:
Responsible Party: Nordic Nanovector
ClinicalTrials.gov Identifier: NCT02657447     History of Changes
Other Study ID Numbers: EudraCT: 2013-003908-39
First Submitted: December 22, 2015
First Posted: January 15, 2016
Last Update Posted: September 13, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nordic Nanovector:
Betalutin
Radioimmunotherapy
Lu-177
Phase I study
ARC
Antibody Radionuclide Conjugate
HH1
Rituximab
177Lu-DOTA-HH1
Lymphoma
Lymphoma Non-Hodgkin
Immune System Diseases
Follicular Lymphoma
Marginal Zone Lymphoma
Lymphoplasmacytoid
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histological Type
Small Lymphocytic Lymphoma
Classical Mantle Cell Lymphoma
Lilotomab
Lutetium (177Lu) lilotomab satetraxetan

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases


To Top